Information Of Lymphoma

According to statistics from the World Health Organization (WHO), the incidence rate of lymphoma is increasing by 7.5% annually, making it one of the malignant tumors with the fastest growth rate over the past decade, and it is also showing a younger trend. Lymphoma can occur in any part of the lymphatic system, with diverse clinical manifestations that affect the immune system and overall health. Its signs and symptoms may include fever, anemia and bleeding manifestations.

There are many types of lymphoma, which can be mainly divided into two major categories: Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL). Research findings show that nodular sclerosis Hodgkin's lymphoma is more common in young people, while mixed cellularity Hodgkin's lymphoma is prevalent in the elderly. The exact etiology of Hodgkin's lymphoma remains unclear, but Epstein-Barr virus (EBV) infection, autoimmune diseases and immunosuppressive states can increase the risk of developing the disease. Individuals with a family history of Hodgkin's lymphoma have a higher risk than the general population.

The most common types of Non-Hodgkin's lymphoma include follicular lymphoma, Burkitt's lymphoma and diffuse large B-cell lymphoma. The incidence rates of different subtypes vary across regions: follicular lymphoma is more common in Western countries, whereas T-cell lymphoma has a higher prevalence in Asia. Statistics indicate that the incidence rate of Non-Hodgkin's lymphoma is slightly higher in males than in females, with a median age of onset between 50 and 70 years old.

Painless lymphadenopathy is the primary initial symptom of most types of lymphoma; unexplained fever is also one of the common symptoms. Treatments for lymphoma vary significantly, depending on the tumor stage, grade, type of lymphoma and various patient-related factors (such as symptoms, age and performance status). The choice of treatment for lymphoma should be determined by professional physicians based on the patient's specific conditions. Traditional treatment methods for hematologic malignancies include chemotherapy and radiotherapy, but these approaches have limited efficacy and relatively severe side effects. Therefore, immunotherapy and targeted drugs have become new research hotspots in the treatment of hematologic malignancies. In addition, CAR-T cell immunotherapy has been approved for clinical application in lymphoma in China. Studies have shown that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, among which 53% reach a state of complete remission. For some complex cases, a combination of multiple treatment modalities may be adopted.

Meanwhile, maintaining healthy living habits—such as a balanced diet, moderate exercise, refraining from smoking and limiting alcohol intake—helps preserve the health of the immune system. Furthermore, avoiding exposure to toxic and chemical substances, as well as risk factors associated with viral infections, also contributes to the prevention of lymphoma. At the same time, standardized diagnosis and treatment are the key determinants for the effective control and ultimate cure of lymphoma.